Background
Aortic stenosis (AS) is one of the most common valvular diseases, with a growing number of patients due to population aging. Among those over 65 years of age, the prevalence of moderate or severe AS is 2 to 4 %, with 1.5 to 3 million afflicted patients in the U.S. alone [1]. Thresholds for intervention have been traditionally defined by assessment of symptoms and echocardiographic parameters of stenosis severity [2, 3]. To date, the major focus in the management of AS has been on the identification of those with symptomatic severe stenosis, in whom aortic valve replacement (AVR) is well established as a life-saving therapy [2, 3]. Nevertheless, AS, even when defined as moderate in severity, may impart hemodynamic effects that could burden patients and potentially be associated with heart failure (HF) and impairment in long-term survival [4‐9]. Such observations have implications for treatment thresholds for patients with AS, but remain limited due to confounding factors such as symptoms, morbidities, and concomitant left ventricular (LV) dysfunction [4‐9]. Accordingly, we undertook this real-world, longitudinal study of a large cohort of patients with moderate AS in order to better define the natural history of moderate AS.
Methods
Study population
The Allina Health System is a private, nonprofit healthcare system that provides care for patients from Minnesota and western Wisconsin, comprised of 3 tertiary and 9 rural hospitals, and more than 90 outpatient clinics. All patients seen between January 2010 and March 2012 in the Allina Health System were considered for enrollment in the present investigation. We examined the initial two-dimensional and Doppler echocardiogram (index echocardiogram) of each patient seen during this time period, and enrolled those with a diagnosis of moderate AS, as defined by the presence of one of the following criteria: (1) peak aortic velocity of 3.0 to 4.0 m/s; (2) mean aortic gradient of 20 to 40 mmHg; (3) aortic valve area (AVA) of 1.0 to 1.5 cm2; (4) indexed AVA of 0.60 to 0.85 cm2/ m2; or (5) a dimensionless index (DI) of 0.25 to 0.50 [10]. Exclusion criteria for the study were: (1) age < 18 years; (2) prior AVR or aortic valve repair; (3) severe mitral, tricuspid, or pulmonary valve disease; (4) severe aortic regurgitation or evidence of supra- or sub-aortic stenosis; and (5) hemodynamic findings consistent with severe AS (i.e., peak aortic velocity ≥4 m/s, mean aortic gradient ≥40 mmHg, or AVA < 1.0 cm2). The study was approved by the Allina Institutional Review Board and was performed in accordance with the Declaration of Helsinki.
Anzeige
Data collection and definitions
Each electronic medical record was reviewed for patient demographics, cardiac symptoms, and morbidities present at the time of the index echocardiogram, and subsequent clinical outcomes. The index echocardiogram was the first echocardiogram during the study period that identified moderate AS patients without exclusion criteria for enrollment. AVA was calculated using the continuity equation. DI was calculated as the ratio of the LV outflow tract velocity time integral (VTI) and to the aortic valve VTI [11]. LV mass index was calculated using the Devereux formula [12]. Patients were classified into New York Heart Association (NYHA) functional class on the basis of the presence of dyspnea. Potential futility markers were defined as: (1) oxygen-dependent severe lung disease; (2) liver disease with model for end-stage liver disease score ≥ 12; (3) end-stage renal disease on dialysis; (4) excessive frailty; (5) severe dementia; or (6) malignancy with life expectancy < 1 year [13‐15].
Clinical outcomes in follow-up evaluations were obtained by review of medical records or telephone interview. The primary clinical outcome of interest in the study was all-cause mortality. Other clinical outcomes were occurrence of HF hospitalization, the combined endpoint of death or HF hospitalization, myocardial infarction (MI), stroke, progression of AS to the severe range, and occurrence of transcatheter or surgical AVR. Standard definitions of HF hospitalization, MI, and stroke were utilized [16, 17].
Data analysis
Three patient groups were defined according to baseline NYHA functional class (I, II, or III/IV). Continuous data were summarized by medians and interquartile ranges (IQR), and compared using a Kruskal-Wallis H test. Categorical variables were summarized by counts (%) and compared using either a Chi-squared test or a Fisher’s exact test as appropriate. For each endpoint, incidence rates per 100 person-years of follow-up and their 95 % confidence intervals (CI) were calculated using a Poisson distribution. Kaplan-Meier survival curves were estimated for each primary endpoint and compared between different NYHA functional classes using a log-rank test, with and without censoring for occurrence of AVR, and with and without exclusion of patients with potential futility markers or LV ejection fraction < 50 %. Further, a one-sample log-rank test was also used to compare the survival free of death for the select patient subgroups with that of the total age- and gender-matched Minnesota population based on the 2013 life tables. Individual expected survival estimates were computed and used to estimate the incident risks of all-cause mortality with a Poisson model adjusted for a sex-specific baseline mortality due to age.
Multivariate Cox proportional hazard models were used to estimate the association between the risk of adverse events and underlying clinical and demographic factors with AVR modeled as a time-dependent variable. All models were stratified by gender, adjusted for age and body surface area, and included NYHA functional class; the body surface area was included to account for the effect of body size on cardiovascular parameters. Other candidate explanatory variables collected at index echocardiogram including continuous measurements of blood pressure, blood pressure medication prescription, mean aortic gradient, peak aortic velocity, LV ejection fraction, body mass index, stroke volume index; binary indicators of moderate or severe mitral regurgitation, moderate or severe tricuspid regurgitation, moderate or severe right ventricular systolic dysfunction, hypertension, diabetes, current smoking status, coronary artery disease, prior MI, prior percutaneous coronary intervention, prior coronary artery bypass grafting, prior stroke or transient ischemic attack, chronic lung disease, peripheral artery disease, dialysis, anemia, malignancy, permanent pacemaker, implanted defibrillator. Also included were futility markers of oxygen-dependent severe lung disease, end-stage renal disease, and excessive frailty; since only two patients in the study had end-stage liver disease and only four had severe dementia, these markers were not included separately but aggregated into broader binary indicators of dementia and liver disease; malignancy was included as a three-level factor: none, malignancy with expected survival of more and of less than one year. A final model was constructed using a stepwise forward selection and backward elimination algorithm with a generalized Akaike information criterion. The estimated associations are reported together with their 95 % CI and p-values. The variable selection and analyses were repeated for patients without futility markers. Data analysis was conducted using SPSS 22 (IBM, Armonk, New York) and R v4.0 in RStudio v1.3 environment (RStudio PBC).
Anzeige
Results
Patient characteristics
Overall, 729 patients with moderate AS (median age, 76 years [IQR: 67 to 84 years]; 59.9 % men) were enrolled in the study (Table 1, Additional file 1: Figure 1). The vast majority (93.1 %) were white, and with a history of hypertension (80.2 %) or dyslipidemia (71.3 %). Coronary artery disease was present in 365 patients (50.1 %) with 197 patients (27.0 %) having prior MI. Overall, 423 patients (58.0 %) had symptoms of dyspnea that were more than mild (i.e., NYHA functional class II or worse). The prevalence of morbidities increased with worse NYHA class, and potential futility markers were present in 90 patients (or 12.3 %) in the overall study population.
Table 1
Baseline patient characteristics
All patients N = 729 | NYHA I N = 306 | NYHA II N = 309 | NYHA III or IV N = 114 |
p
| |
|---|---|---|---|---|---|
Age (yrs) | 76 (67, 84) | 74 (66, 83) | 77 (68, 85) | 77 (69, 84) | 0.107 |
Women | 292 (40.1) | 139 (45.4) | 116 (37.5) | 37 (32.5) | 0.027 |
Caucasian | 679 (93.1) | 287 (93.8) | 289 (93.5) | 103 (90.4) | 0.435 |
Body mass index (kg/m2) | 27.7 (24.5, 32.2) | 28.0 (24.8, 32.3) | 27.9 (24.5, 32.2) | 26.8 (23.7, 31.9) | 0.290 |
Hypertension | 585 (80.2) | 236 (77.1) | 251 (81.2) | 98 (86.0) | 0.110 |
Diabetes | 236 (32.4) | 81 (26.5) | 112 (36.2) | 43 (37.7) | 0.014 |
Dyslipidemia | 520 (71.3) | 201 (65.7) | 240 (77.7) | 79 (69.3) | 0.004 |
Current smoking | 68 (9.3) | 28 (9.2) | 29 (9.4) | 11 (9.6) | 0.987 |
Coronary artery disease | 365 (50.1) | 101 (33.0) | 196 (63.4) | 68 (59.6) | < 0.001 |
Prior myocardial infarction | 197 (27.0) | 32 (10.5) | 114 (36.9) | 51 (44.7) | < 0.001 |
Prior PCI | 216 (29.6) | 61 (19.9) | 118 (38.2) | 37 (32.5) | < 0.001 |
Prior CABG | 138 (18.9) | 30 (9.8) | 79 (25.6) | 29 (25.4) | < 0.001 |
Atrial fibrillation or flutter | 286 (39.2) | 91 (29.7) | 134 (43.4) | 61 (53.5) | < 0.001 |
Stroke or TIA | 128 (17.6) | 48 (15.7) | 52 (16.8) | 28 (24.6) | 0.095 |
Chronic lung disease | 146 (20.0) | 40 (13.1) | 74 (23.9) | 32 (28.1) | < 0.001 |
O2-dependent | 31 (4.3) | 8 (2.6) | 17 (5.5) | 6 (5.3) | 0.163 |
Peripheral artery disease | 121 (16.6) | 37 (12.1) | 63 (20.4) | 21 (18.4) | 0.018 |
CKD stage ≥ III | 207 (28.6) | 45 (14.8) | 109 (35.5) | 53 (46.9) | < 0.001 |
Dialysis | 28 (3.8) | 4 (1.3) | 13(4.2) | 11 (9.6) | 0.001 |
Anemia | 350 (48.0) | 120 (39.2) | 152 (49.2) | 78 (68.4) | < 0.001 |
Permanent pacemaker | 101 (13.9) | 18 (5.9) | 60 (19.4) | 23 (20.2) | < 0.001 |
Implanted defibrillator | 70 (9.6) | 11 (3.6) | 32 (10.4) | 27 (23.7) | < 0.001 |
Severe liver cirrhosis | 2 (0.3) | 0 (0) | 1 (0.3) | 1 (0.9) | 0.288 |
Severe dementia | 4 (0.5) | 0 (0) | 1 (0.3) | 3 (2.6) | 0.013 |
Life-threatening malignancy | 18 (2.5) | 9 (2.9) | 7 (2.3) | 2 (1.8) | 0.809 |
Excessive frailty | 25 (3.4) | 4 (1.3) | 13 (4.2) | 8 (7.0) | 0.006 |
Medical therapy | |||||
Anti-platelet | 527 (72.3) | 203 (66.3) | 233 (75.4) | 91 (79.8) | 0.006 |
Warfarin or NOAC | 203 (27.8) | 61 (19.9) | 97 (31.4) | 45 (39.5) | < 0.001 |
ACE-i or ARB | 404 (55.4) | 141 (46.1) | 193 (62.5) | 70 (61.4) | < 0.001 |
Beta-blocker | 511 (70.1) | 172 (56.2) | 239 (77.3) | 100 (87.7) | < 0.001 |
Nitrates | 83 (11.4) | 19 (6.2) | 38 (12.3) | 26 (22.8) | < 0.001 |
Diuretic | 379 (52.0) | 118 (38.6) | 176 (57.0) | 85 (74.6) | < 0.001 |
Aldosterone antagonist | 54 (7.4) | 11 (3.6) | 22 (7.1) | 21 (18.4) | < 0.001 |
Overall, the median AVA was 1.51 cm2 (IQR: 1.34 to 1.73 cm2) with a median aortic valve gradient of 9.1 mmHg (IQR: 5.9 to 14.0 mmHg) (Table 2). The LV ejection fraction was preserved in the majority of patients (71.6 %) with a median value of 58 % (IQR: 45 % to 63 %). Worse NYHA class was associated with lower aortic valve velocity, mean aortic gradient, LV ejection fraction, and stroke volume index (all p < 0.001). Higher AVA, larger LV end-diastolic diameter, and more mitral and tricuspid regurgitation also were more common in those with worse NYHA functional class (all p < 0.01).
Table 2
Echocardiographic data
All patients N = 729 | NYHA I N = 306 | NYHA II N = 309 | NYHA III or IV N = 114 |
p
| |
|---|---|---|---|---|---|
Peak aortic velocity (m/s) | 2.1 (1.7, 2.6) | 2.3 (1.9, 2.8) | 2.0 (1.6, 2.3) | 1.8 (1.5, 2.2) | < 0.001 |
Mean aortic gradient (mmHg) | 9.1 (5.9, 14.0) | 11.8 (7.6, 16.5) | 8.0 (5.3, 11.8) | 6.4 (4.4, 11.1) | < 0.001 |
Aortic valve area (cm2) | 1.51 (1.34, 1.73) | 1.48 (1.30, 1.70) | 1.55 (1.37, 1.74) | 1.57 (1.38, 1.75) | 0.004 |
Aortic valve area index (cm2/ m2) | 0.79 (0.69, 0.89) | 0.76 (0.68, 0.86) | 0.80 (0.71, 0.91) | 0.79 (0.70, 0.90) | 0.002 |
Dimensionless index | 0.44 (0.39, 0.47) | 0.43 (0.38, 0.47) | 0.44 (0.40, 0.47) | 0.44 (0.38, 0.48) | 0.196 |
Stroke volume index (ml/m2) | 33.8 (25.6, 41.2) | 37.1 (30.0, 44.3) | 31.4 (25.1, 39.5) | 28.2 (23.0, 36.0) | < 0.001 |
Stroke volume index <35 ml/m2 | 357 (54.3) | 104 (38.5) | 178 (62.7) | 75 (72.1) | < 0.001 |
Left ventricular EDD (cm) | 4.8 (4.2, 5.4) | 4.5 (4.0, 5.1) | 4.8 (4.2, 5.4) | 5.4 (4.9, 6.0) | < 0.001 |
Left ventricular mass index (g/m2) | 112 (91, 137) | 101 (83, 124) | 116 (96, 139) | 132 (108, 161) | < 0.001 |
Left ventricular ejection fraction (%) | 58 (45, 63) | 60 (58, 65) | 55 (40, 63) | 38 (23, 58) | < 0.001 |
Left ventricular ejection fraction <50 % | 207 (28.4) | 23 (7.5) | 112 (36.2) | 72 (63.2) | < 0.001 |
E/e’ | 12.0 (9.0, 16.0) | 11.0 (8.5, 15.0) | 12.0 (9.0, 17.0) | 13.0 (10.9, 18.0) | 0.006 |
Left atrial volume index (ml/ m2) | 37 (29, 49) | 34 (27, 46) | 36 (29, 50) | 45 (34, 56) | < 0.001 |
RV systolic pressure (mmHg) | 35 (28, 44) | 33 (27, 40) | 36 (28, 46) | 43 (36, 51) | < 0.001 |
≥ moderate MR | 61 (8.4) | 10 (3.3) | 34 (11.1) | 17 (14.9) | < 0.001 |
≥ moderate TR | 96 (13.5) | 31 (10.4) | 38 (12.7) | 27 (24.3) | 0.001 |
≥ moderate RV dysfunction | 33 (4.7) | 2 (0.7) | 13 (4.3) | 18 (16.8) | < 0.001 |
Clinical outcomes
Clinical follow-up was complete in all patients with a median time of 5.0 years (IQR: 2.0 to 8.1 years), and any death occurred in 453 patients (or 62.1 %) with an estimated survival time of 5.5 years (95 % CI: 4.8 to 6.2 years). Overall, 5-year survival was 52.3 % (95 % CI: 48.6 % to 56.0 %), with an incidence of 12.6 (95 % CI: 11.4 to 13.7) per 100 person-year (Fig. 1; Table 3). In the entire study group, HF hospitalization occurred in 211 patients (or 28.9 %), with an incidence of 6.7 (95 % CI: 5.8 to 7.6) per 100 person-year (Table 3). For the combined endpoint of death or HF hospitalization, the 5-year survivorship was 43.2 % (95 % CI: 39.5 % to 46.9 %), with an incidence of 16.3 (95 % CI: 14.9 to 17.7) per 100 person-year (Table 3).
Fig. 1
Survival of patients with moderate aortic stenosis. Observed survival free of all-cause mortality (solid) for the entire study cohort in comparison to the expected survival, based on the age- and sex-matched total Minnesota population (dashed), is shown
×
![]()
Table 3
Major adverse clinical events
All patients | Overall N = 729 | NYHA I N = 306 | NYHA II N = 309 | NYHA III or IV N = 114 |
P
|
|---|---|---|---|---|---|
Any death | 12.6 (11.4, 13.7) | 7.9 (6.6, 9.2) | 15.1 (13.1, 17.1) | 25.2 (20.2, 30.3) | < 0.001 |
Heart failure hospitalization | 6.7 (5.8, 7.6) | 4.5 (3.4, 5.5) | 7.9 (6.3, 9.4) | 13.9 (9.8, 18.1) | 0.014 |
Any death or heart failure hospitalization | 16.3 (14.9, 17.7) | 10.7 (9.2, 12.3) | 19.5 (17.0, 22.0) | 33.4 (26.9, 39.8) | < 0.001 |
Progression to severe aortic stenosis* | 3.9 (3.1, 4.7) | 4.3 (3.1, 5.5) | 3.5 (2.3, 4.7) | 3.2 (0.8, 5.5) | 0.014 |
AVR | 2.5 (1.9, 3.0) | 3.0 (2.2, 3.9) | 1.9 (1.2, 2.7) | 1.9 (0.5, 3.4) | 0.001 |
Any death, heart failure hospitalization, or AVR | 18.4 (16.9, 20.0) | 13.1 (11.3, 15.0) | 21.1 (18.5, 23.7) | 35.4 (28.7, 42.2) | < 0.001 |
Myocardial infarction | 2.3 (1.8, 2.8) | 1.5 (0.9, 2.1) | 3.6 (2.5, 4.6) | 1.3 (0.2, 2.5) | 0.002 |
Stroke | 2.0 (1.5, 2.5) | 1.8 (1.2, 2.5) | 2.1 (1.3, 2.8) | 2.8 (1.0, 4.5) | 0.824 |
Patients without severe morbidities | Overall N = 639 | NYHA I N = 283 | NYHA II N = 267 | NYHA III or IV N = 89 |
P
|
|---|---|---|---|---|---|
Any death | 10.8 (9.7, 12.0) | 7.0 (5.8, 8.2) | 13.0 (11.0, 14.9) | 23.2 (17.8, 28.5) | < 0.001 |
Heart failure hospitalization | 6.2 (5.4, 7.1) | 4.4 (3.3, 5.4) | 7.2 (5.7, 8.8) | 13.6 (9.1, 18.1) | 0.018 |
Any death or heart failure hospitalization | 14.3 (13.0, 15.7) | 9.8 (8.2, 11.3) | 16.9 (14.6, 19.3) | 30.7 (24.0, 37.5) | < 0.001 |
Progression to severe aortic stenosis | 3.9 (3.0, 4.7) | 4.4 (3.2, 5.6) | 3.3 (2.1, 4.5) | 3.2 (0.6, 5.7) | 0.012 |
AVR | 2.5 (1.9, 3.0) | 3.1 (2.2, 3.9) | 1.9 (1.1, 2.6) | 2.0 (0.4, 3.6) | 0.003 |
Any death, heart failure hospitalization, or AVR | 16.4 (14.9, 17.9) | 12.1 (10.4, 13.9) | 18.5 (15.9, 21.0) | 33.1 (25.9, 40.3) | < 0.001 |
Myocardial infarction | 2.2 (1.7, 2.7) | 1.4 (0.9, 2.0) | 3.5 (2.5, 4.6) | 1.3 (0.03, 2.6) | 0.002 |
Stroke | 2.0 (1.5, 2.5) | 1.9 (1.2, 2.6) | 1.9 (1.1, 2.6) | 3.0 (1.0, 5.0) | 0.657 |
Worse NYHA class was related to higher rates of any death, HF hospitalization and the combined endpoint of death or HF hospitalization (all p < 0.05) (Table 3). Notably, among 306 patients with minimal or no symptoms (i.e., NYHA class I), the 5-year survival was 66.1 % (95 % CI: 60.8 % to 71.4 %), with an incidence of 7.9 (95 % CI: 6.6 to 9.2) per 100 person-year (Fig. 2; Table 3). For the combined endpoint of death or HF hospitalization, the 5-year survival for the NYHA class I patients was 57.1 % (95 % CI: 51.4–62.8 %), with an incidence of 10.7 (95 % CI: 9.2 to 12.3) per 100 person-year (Fig. 2; Table 3).
Anzeige
Fig. 2
Survival according to baseline New York Heart Association (NYHA) functional class for the entire cohort. a Survival free of death. b Survival free of death and heart failure (HF) hospitalization
×
![]()
The trends in the rates of death and the combined endpoint of death or HF hospitalization were similar when patients with potential futility markers were excluded (all p < 0.001) (Table 3). Among the 639 patients without potential futility markers, the survival was 57.4 % (95 % CI: 53.5–61.3 %) at 5 years, and was 47.8 % (95 % CI: 43.9–51.7 %) at 5 years for the combined endpoint of death or HF hospitalization. Of note, for patients who had minimal or no symptoms (NYHA I) and who also were without potential futility markers (n = 283), the 5-year overall survival and survival free of the combined endpoint of death or HF hospitalization were 70.5 % (95 % CI: 65.2–75.8 %) and 60.7 % (95 % CI: 55.0–66.4 %), respectively. In addition, the 5-year overall survival was 58.2 % (95 % CI: 53.9–62.5 %) among 522 patients with preserved LV systolic function (≥50 %), while in whom with NYHA I, the survival was 67.6 % (95 % CI: 62.1–73.1 %) at 5 years. Moreover, this survivorship was similar when analyses were restricted to patients with minimal or no symptoms, without potential futility markers, and with preserved LV ejection fraction. In these patients (n = 262), the 5-year survival was 71.9 % (95 % CI: 66.4–77.4 %) with a death rate of 6.8 (95 % CI: 5.5 to 8.0) per 100 person-year.
Progression to AVR and censoring
Echocardiographic follow-up was available in 517 patients (71 % of the cohort), at a median interval of 4.3 years (IQR: 2.3 to 6.8 years). Among them, 89 of these patients (17.2 %) had progression to severe AS, with an incidence of 3.9 (95 % CI: 3.1 to 4.7) per 100 person-year (Fig. 3; Table 3). Overall, AVR occurred in 83 patients (transcatheter, 55.4 %; surgical, 44.6 %), with an incidence of 2.5 (95 % CI: 1.9, 3.0) per 100 person-year (Fig. 3; Table 3). The median time to AVR for these patients was 4.4 years (IQR: 1.9 to 7.9 years).
Fig. 3
Disease progression for patients with moderate aortic stenosis. a Incidence of disease progression to severe aortic stenosis among patients with echocardiography in follow-up (n = 517). b Incidence of aortic valve replacement in the entire cohort (n = 729)
×
![]()
Anzeige
Survivorship analyses were similar with and without censoring for occurrence of AVR in follow-up. Overall, the 5-year survival and survival free of the combined endpoint of death or HF hospitalization were 52.7 % (95 % CI: 49.0 % to 56.4 %) and 43.5 % (95 % CI: 39.8 % to 47.2 %) with censoring for AVR, respectively. For the patients who had minimal or no symptoms (i.e., NYHA class I), these estimates were 66.4 % (95 % CI: 60.9 % to 71.9 %) and 57.3 % (95 % CI: 51.6 % to 63.0 %), respectively. Similarly, the survivorship was unchanged in a subset of patients without severe co-morbidities and with censoring for occurrence of AVR, with a 5-year survival of 58.0 % (95 % CI: 54.1 % to 61.9 %) (Fig. 4). For patients without futility markers and who had minimal or no symptoms, the estimate survival with censoring for AVR was 70.8 % (95 % CI: 65.3 % to 76.3 %) (Fig. 4). Moreover, for patients with minimal or no symptoms, no potential futility markers, and preserved LV function, the 5-year survival with censoring for AVR was 72.0 % (95 % CI: 66.3–77.7 %) (Additional file 1: Figure 2). For the combined endpoint of death or HF hospitalization, this survival was 61.7 % (95 % CI: 55.6–67.8 %).
Fig. 4
Survival in patients with moderate aortic stenosis who were without severe morbidities, with survival times censored at aortic valve replacement (N = 639). a Observed survival (solid) in comparison to the expected survival based on the age- and sex-matched total Minnesota population (dashed). b Observed survival according to New York Heart Association (NYHA) functional class
×
![]()
Multivariate models
In univariate and survival analyses, traditional prognostic echocardiographic parameters (e.g., LV ejection fraction < 50 %, stroke volume index < 35 ml/m2, and rapid AS progression rate [Vmax > 0.3 m/s/y]) were associated with worse outcomes in this cohort of patients (Additional file 1: Figures 3–5). In multivariate models, age, NYHA functional class, low LV ejection fraction and high peak aortic velocity were associated with all-cause mortality with AVR modeled as a time-dependent variable (Table 4). These associations were present in analyses of the overall population, as well as in analyses that excluded patients with potential futility markers (Table 4). These same variables were also independently associated with the occurrence of the composite endpoint of death or HF hospitalization in patients with or without potential futility markers (Table 4).
Table 4
Multivariate models. Cox proportional hazard regression analyses for predicting outcomes are shown
Variables | All patients | Patients without severe morbidities | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any death | Any death/HF hospitalization | Any death | Any death/HF hospitalization | |||||||||
HR | 95 % CI | p value | HR | 95 % CI | p value | HR | 95 % CI | p value | HR | 95 % CI | p value | |
Age (per 1-year) | 1.04 | 1.03–1.05 | < 0.001 | 1.03 | 1.02–1.05 | < 0.001 | 1.05 | 1.04–1.06 | < 0.001 | 1.04 | 1.03–1.05 | < 0.001 |
BSA (per 1 kg/m2) | 0.50 | 0.29–0.85 | 0.010 | 0.60 | 0.37–0.98 | 0.041 | – | – | – | – | – | – |
Occurrence of AVR* | 0.77 | 0.49–1.19 | 0.237 | 1.00 | 0.63–1.57 | 0.986 | 0.86 | 0.54–1.36 | 0.510 | 0.89 | 0.55–1.45 | 0.643 |
NYHA II | 1.39 | 1.09–1.76 | 0.007 | 1.37 | 1.10–1.70 | 0.005 | 1.37 | 1.06–1.78 | 0.016 | 1.29 | 1.02–1.64 | 0.034 |
NYHA III or IV | 1.67 | 1.20–2.31 | 0.002 | 1.38 | 1.01–1.90 | 0.045 | 1.72 | 1.20–2.47 | 0.003 | 1.45 | 1.02–2.04 | 0.036 |
Stroke/TIA | 1.44 | 1.14–1.83 | 0.002 | 1.32 | 1.05–1.66 | 0.016 | 1.58 | 1.22–2.03 | < 0.001 | 1.37 | 1.07–1.75 | 0.012 |
Hypertension | – | – | – | 1.41 | 1.10–1.82 | 0.007 | – | – | – | 1.35 | 1.03–1.78 | 0.031 |
Diabetes | 1.25 | 1.01–1.54 | 0.039 | 1.24 | 1.02–1.52 | 0.030 | – | – | – | 1.26 | 1.01–1.57 | 0.040 |
Chronic lung disease | 1.53 | 1.22–1.91 | < 0.001 | 1.35 | 1.09–1.68 | 0.007 | 1.52 | 1.17–1.96 | 0.002 | 1.44 | 1.12–1.85 | 0.004 |
CKD stage ≥ III | 1.43 | 1.16–1.77 | 0.001 | 1.24 | 1.00-1.53 | 0.046 | 1.41 | 1.12–1.78 | 0.003 | 1.33 | 1.06–1.67 | 0.014 |
Anemia | 1.60 | 1.30–1.98 | < 0.001 | 1.50 | 1.23–1.83 | < 0.001 | 1.64 | 1.32–2.04 | < 0.001 | 1.45 | 1.18–1.79 | 0.001 |
Liver cirrhosis | 3.36 | 1.75–6.45 | < 0.001 | 2.70 | 1.41–5.15 | 0.003 | 3.48 | 1.68–7.22 | < 0.001 | 2.22 | 1.07–4.59 | 0.032 |
Dementia | 1.85 | 1.31–2.61 | < 0.001 | 1.77 | 1.27–2.46 | 0.001 | 1.98 | 1.33–2.95 | < 0.001 | 1.59 | 1.07–2.35 | 0.022 |
Malignancy | 11.75 | 6.89–20.06 | < 0.001 | 7.57 | 4.50-12.73 | < 0.001 | – | – | – | – | – | – |
Excessive frailty | 2.38 | 1.51–3.76 | < 0.001 | 2.90 | 1.85–4.56 | < 0.001 | – | – | – | – | – | – |
LV ejection fraction (per 1 %) | 0.98 | 0.98–0.99 | 0.001 | 0.98 | 0.97–0.99 | < 0.001 | 0.98 | 0.97–0.99 | 0.002 | 0.97 | 0.97–0.98 | < 0.001 |
Peak aortic velocity (per 1 m/s) | 1.37 | 1.13–1.67 | 0.002 | 1.37 | 1.14–1.64 | 0.001 | 1.34 | 1.08–1.67 | 0.008 | 1.39 | 1.14–1.70 | 0.001 |
≥ moderate TR | 1.47 | 1.13–1.92 | 0.005 | 1.32 | 1.01–1.72 | 0.041 | 1.47 | 1.09–1.98 | 0.012 | 1.43 | 1.08–1.91 | 0.014 |
≥ moderate RV dysfunction | 2.58 | 1.61–4.16 | < 0.001 | 2.03 | 1.27–3.24 | 0.003 | 2.59 | 1.46–4.60 | 0.001 | 1.73 | 1.00–2.99 | 0.051 |
Anzeige
Discussion
The present investigation is a real-world examination of outcomes in patients with moderate AS evaluated in a large health system that includes outpatient care clinics and tertiary referral centers. The principal findings are: (1) Patients with moderate AS can have impaired prognosis, with a 5-year survival only 52 % observed in this study; (2) The heightened risk of death remains even when focusing on patients with minimal or no symptoms, no LV systolic dysfunction and no potential futility markers, in whom the 5-year survival was only 72 %; (3) These outcomes were observed while there were low rates of progression to severe AS (∼4 % per year) and need for AVR (∼2.5 % per year), and after accounting for the occurrence of such events with censoring; (4) Advanced age, worse NYHA functional class, low ejection fraction, high peak aortic velocity and severe comorbidities were associated with worse outcomes. Taken together, these findings highlight the prognostic impact of AS, even when only moderate in severity.
While there has been intense focus on the evaluation and management of patients with severe AS, those with moderate disease may be vulnerable with an impaired prognosis. The present investigation was undertaken as a real-world, longitudinal study of 729 patients with moderate AS (median AVA, 1.5 cm2) observed over a median follow-up of 5.0 years. In our study, the 5-year survival was 52 % for the entire cohort. Hospitalization for HF occurred at rate of ~ 6.0 % per year. Certainly, this survivorship is better than what would be expected for severe, symptomatic aortic stenosis, where the mortality rates are commonly ~ 25 % per year or more [7]. Nevertheless, the annual mortality rate of 12.6 % in our study is notable, and markedly worse than expected. Our findings mirror the results of Strange et al. [7], who utilized a large national echocardiography database in Australia and reported a 5-year mortality rate of 56 % for 3,315 patients with moderate AS. Similarly, in a separate study of 508 moderate AS patients by Delesalle et al., the 6-year survival was only 53 % [8]. Taken together, the risk of death in patients with moderate AS is remarkable, and deserves further scrutiny regarding potential management to improve their prognosis.
Importantly, our findings extend the results of other studies, with a more granular analysis of the influence of symptoms, LV systolic function, occurrence of AVR, and morbidities on survival of these patients. Not surprisingly, worse functional class was strongly associated with the presence of morbidities and poor survival, with an annual mortality rate of 25 % for those with most impairment (i.e., NYHA III/IV), and many morbidities were independently predictive of the long-term outcomes. Nonetheless, for those patients with minimal or no symptoms and with no evidence of futility, the 5-year survival was still only 71 % with an annualized death rate of ∼7.0 % per year. This survivorship also was similar when we restricted analyses to those patients with minimal impairment, who had preserved LV function and no futility markers, with and without censoring for occurrence of AVR (i.e., 5-year survival free of all-cause mortality, ~ 72 %).
While a study of a younger population of patients with moderate AS (n = 514) by Lancelotti et al. [4] found a 4-year survival of 89 %, it is recognized that AS, even when not severe, can impart significant myocardial architectural changes. Increases in LV mass, mid-wall fibrosis, and extracellular volume can occur with progression of AS, even when not severe [18‐22]. As reversibility of cardiac damage with AVR has been shown in severe AS, there is rationale for consideration of AVR in patients with moderate AS and LV dysfunction [23‐26]. Whether such therapy should be extended to all patients with moderate AS, with or without preserved LV function, may be a consideration. The high mortality rate in our study, as has been observed in others, invites scrutiny into the possible benefit of AVR in patients with preserved LV function and with minimal clinical impairment, especially given that procedural mortality with modern transcatheter or surgical techniques is now relatively low, and often < 1–3 % [27]. Certainly, a survival benefit of such therapy for patients with moderate AS would only be hypothetical until tested in prospective, randomized clinical trials [28].
The present study was a longitudinal, yet retrospective analysis of patients from hospitals and outpatient clinics, therefore subject to selection bias. Nonetheless, our findings suggest the need for close clinical follow-up and better clinical management in patients with moderate AS, who are at significant risk of death, even when minimally or asymptomatic. A single positive echocardiographic parameter for defining moderate AS also posed limitations. In addition, in the cohort of patients with no symptoms, no severe morbidities, and preserved LV function, some patients with a prior history of myocardial infarction were included and that morbidity could have impacted their survival. Lastly, we were limited in our ability to adjudicate cardiovascular from non-cardiovascular deaths, which would be important to determine a potential protective role for AVR.
Conclusions
Our study demonstrates significant mortality rates for patients with moderate AS in the setting of hospital and outpatient clinic, and thus highlights the need to reexamine thresholds for clinical surveillance and intervention in patients with moderate AS.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-01901-1.
Acknowledgements
Not applicable.
Ethics approval and consent to participate
The study was approved by the Allina Institutional Review Board and was performed in accordance with the Declaration of Helsinki. Written consent to participate was obtained from study participants.
Consent for publication
Not required.
Competing interests
Dr. Gössl serves as a consultant for Abbott Structural. Dr. Garcia receives Institutional Research grants from Edwards Lifesciences and Boston Scientific; proctors Edwards Lifesciences. Dr. Sarano is a consultant for Cryolife inc, Edwards Lifesciences LLC. Dr. Cavalcante serves as a consultant for Boston Scientific, Abbott Vascular; a speaker for Medtronic, Circle Cardiovascular Imaging, and Siemens Healthineers; receives research grant support from Circle Cardiovascular Imaging, Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott Vascular. Dr. Bae is a consultant for Abbott Structural. Dr. Sorajja is a consultant for Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Medtronic, TeleFlex, WL Gore. The other authors report no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.